BALA CYNWYD, Pa., March 27, 2023 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Berkshire Grey, Inc. (Nasdaq- BGRY)
Under the terms of the deal, Berkshire Grey will be acquired by SoftBank Group Corp. and its affiliate (together, “SoftBank”). Berkshire Grey stockholders will receive $1.40 per share in an all-cash transaction worth approximately $375 million. The investigation concerns whether the Berkshire Grey Board breached its fiduciary duties to shareholders by failing to conduct a fair process, and whether SoftBank is paying too little for the Company. For example, the deal consideration is below the 52-week high of $3.72 for the Company’s shares.
Additional information can be found at https://www.brodskysmith.com/cases/berkshire-grey-inc-nasdaq-bgry/.
Jounce Therapeutics, Inc. (Nasdaq- JNCE)
Under the terms of the agreement, Jounce will be acquired by Concentra Biosciences, LLC (“Concentra”). Jounce stockholders will receive $1.85 per share in an all-cash transaction plus a non-tradeable contingent value right (the “CVR”). The investigation concerns whether the Jounce Board breached its fiduciary duties to shareholders by failing to conduct a fair process, and whether Concentra is paying too little for the Company.
Additional information can be found at https://www.brodskysmith.com/cases/jounce-therapeutics-inc-nasdaq-jnce/.
Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.
